The selective FLT3 inhibitor gilteritinib (Xospata, Astellas) led to significantly longer overall survival, higher response rates and fewer adverse events than salvage chemotherapy in adults with FLT3-positive relapsed or refractory (R/R) acute myeloid leukemia (AML), according to interim results from the phase 3 ADMIRAL trial.
“These findings change the treatment paradigm for this patient population,” noted investigator Alexander Perl, MD, from Penn Medicine’s Abramson